Biocept, Inc.
BIOC
BIOC was delisted on the 24th of October, 2023.
26 hedge funds and large institutions have $8.12M invested in Biocept, Inc. in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 5 closing their positions.
124% more call options, than puts
Call options by funds: $649K | Put options by funds: $290K
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
24% more funds holding
Funds holding: 21 → 26 (+5)
20% more capital invested
Capital invested by funds: $6.76M → $8.12M (+$1.36M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Globeflex Capital
San Diego,
California
|
+$1.25M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$800K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$408K |
| 4 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
+$202K |
| 5 |
Renaissance Technologies
New York
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$658K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$322K |
| 3 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$302K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$229K |
| 5 |
VF
Virtu Financial
New York
|
-$80K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
26
Sabby Management
Miami Beach,
Florida
| – | -$322K | -2,563 | Closed |
|
|
HSA
27
Hussman Strategic Advisors
Ellicott City,
Maryland
| – | -$302K | -2,400 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$80K | -633 | Closed |
|
29
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$21K | -167 | Closed |
|
|
RFA
30
Reilly Financial Advisors
La Mesa,
California
| – | -$1K | -7 | Closed |
|
BIOC Hedge Fund Activity: Q3 2021 in Review
26 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q3 2021, worth a combined $8.12M — up 20% from $6.76M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BIOC positions and 5 closed out — a net gain of 5 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Globeflex Capital, opening a new position worth an estimated $1.25M. The largest seller was Morgan Stanley, cutting an estimated $658K.
- 26 institutional investors held Biocept, Inc. (BIOC) as of Q3 2021, up from 21 in Q2 2021.
- Funds reported $8.12M of Biocept, Inc. stock for Q3 2021, up 20% quarter-over-quarter.
- 10 funds opened new Biocept, Inc. positions in Q3 2021 and 5 closed out, a net change of +5 holders.
- The largest Biocept, Inc. buyer in Q3 2021 was Globeflex Capital, an estimated $1.25M added.
- The largest Biocept, Inc. seller in Q3 2021 was Morgan Stanley, an estimated $658K sold.
Based on aggregated 13F filings for Q3 2021.